MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Psychosis"

  • 2023 International Congress

    Development of an Item Bank for Assessing Psychosis in Parkinson’s Disease: A Systematic Review

    G. Mangone, M. Tosin, C. Goetz, G. Stebbins, T. Mestre (Chicago, USA)

    Objective: This study aimed to develop an item bank for assessing psychosis in Parkinson's disease (PD). Background: Psychosis is a common and debilitating symptom in…
  • 2023 International Congress

    Safety assessment of pimavanserin in Parkinson’s disease psychosis patients: Evidence from a systematic review and meta-analysis of randomized controlled trials

    G. Bano, A. Sharma (New Delhi, India)

    Objective: This systematic review and meta-analysis aimed to assess the safety profile of pimavanserin in Parkinson’s disease psychosis (PDP) patients from the available randomized controlled…
  • 2023 International Congress

    Parkinson’s disease-associated psychosis in a Brazilian sample: worse cognitive outcomes, higher LEDD and longer disease duration.

    H. Dourado, C. Lobo, G. Procópio, AE. Lima, MA. Silveira, L. de Almeida, IJ. Oliveira, G. Valença (Salvador, Brazil)

    Objective: To describe the prevalence of Parkinson's Disease (PD) associated psychosis (PDAP) at a Brazilian movement disorders outpatient and to evaluate its associated factors. Background:…
  • 2023 International Congress

    Effect of ADX-88178, a highly-selective mGlu4 PAM, on parkinsonism, dyskinesia and psychosis-like behaviours in the MPTP-lesioned marmoset

    I. Frouni, C. Kwan, D. Bédard, W. Kang, S. Nuara, J. Gourdon, P. Huot (Montreal, Canada)

    Objective: To investigate the effect of the metabotropic glutamate 4 (mGlu4) positive allosteric modulator (PAM) ADX-88178 on parkinsonism, dyskinesia and psychosis-like behaviours (PLBs) in the…
  • 2023 International Congress

    Identifying delirium in Parkinson’s: evaluation of existing tools and measures

    R. Lawson, S. Richardson, F. Gerakios, G. Bate (Newcastle upon Tyne, United Kingdom)

    Objective: To evaluate the diagnostic accuracy of tools to identify delirium in inpatients with Parkinson’s disease (PD). Background: Delirium is a serious acute state of…
  • 2023 International Congress

    Neuropsychiatric Symptoms in Early-Onset Parkinson’s Disease

    C. Piat, E. Camerucci, A. Mullan, K. Ghoniem, J. Jacobson, G. Patanè, P. Turcano, R. Savica (Rochester, USA)

    Objective: To describe the neuropsychiatric symptoms of Early-Onset Parkinson’s Disease (EOPD) patients in an incident cohort study from 1991 to 2010 in Olmsted County, Minnesota…
  • 2023 International Congress

    Olfactory dysfunction and neuropsychiatric manifestations in early drug-naïve Parkinson’s disease

    P. Julayanont (Phoenix, USA)

    Objective: To determine the severity of various neuropsychiatric disturbances in drug-naïve Parkinson’s disease (PD) patients with (PD-OD) and without olfactory dysfunction (PD-NOD) compared to healthy…
  • 2023 International Congress

    Development and Clinimetric Testing Plan for the MDS Parkinson’s Disease Psychosis Rating Scale (MDS-PDPRS)

    M. Tosin, T. Mestre, G. Stebbins, G. Mangone, S. Videmsky, S. Ali, D. Aarsland, J. Goldman, T. Khoo, S. Lewis, P. Martinez-Martin, O. Ojo, J. Pagonabarraga, A. Schrag, D. Weintraub, C. Goetz (Chicago, USA)

    Objective: Present the development process and clinimetric testing plan for the International Parkinson and Movement Disorder Society Parkinson's Disease Psychosis Rating Scale (MDS-PDPRS). Background: Psychosis…
  • 2023 International Congress

    Clinico-genetic analysis of patients with Parkinson’s disease and GBA mutations from a tertiary care teaching centre in India

    S. Kamath, V. Holla, P. Phulpagar, N. Kamble, R. Yadav, B. Muthusamy, PK. Pal (Bangalore, India)

    Objective: To describe the clinico-genetic association of PD patients with heterozygous GBA mutations (PDwG). Background: Parkinson’s disease (PD) is currently understood to be the outcome…
  • 2023 International Congress

    Jumping to Conclusions bias, psychosis and impulsivity in early stages of Parkinson’s disease

    IP. Pachi, VP. Papadopoulos, CK. Koros, AMS. Simitsi, AB. Bougea, MB. Bozi, NP. Papagiannakis, RFP. Soldatos, DK. Kolovou, GP. Pantes, NS. Scarmeas, LAX. Xenaki, GP. Paraskevas, KV. Voumvourakis, SGP. Papageorgiou, KK. Kollias, NS. Stefanis, LS. Stefanis (Athens, Greece)

    Objective: The aim was to explore the correlations between Jumping to Conclusions (JtC) tendency and neuropsychiatric features in patients with early Parkinson’s disease (PD). Background:…
  • 1
  • 2
  • 3
  • …
  • 12
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
      • Effect of marijuana on Essential Tremor: A case report
      • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
      • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
      • Insulin dependent diabetes and hand tremor
      • Patients with Essential Tremor Live Longer than their Relatives
      • Help & Support
      • About Us
      • Cookies & Privacy
      • Wiley Job Network
      • Terms & Conditions
      • Advertisers & Agents
      Copyright © 2023 International Parkinson and Movement Disorder Society. All Rights Reserved.
      Wiley